fda peptide regulations bpc-157 igf-1 cerebrolysin TB 500 vs BPC 157: Comprehensive comparison of healing peptides BPC-157 FDA Approval Status: Is

The marketing narrative that PDA is a "legal alternative" to BPC-157 rests on the unsupported argument that the FDA's Category 2 classification does not cover arginate salt variants

[DOI] [PubMed] [Google Scholar] 75.Maeda N, Funahashi T, Hibuse T, Nagasawa A, Kishida K, et al

It also states that available safety information is insufficient to know whether harm could occur

Joint issues: TB-500 for systemic joint inflammation

(2008) went on to compare the effectiveness of both systemic (intraperitoneal) and local treatment (as a thin cream layer) over a period of 14 days in crushed muscle (gastrocnemius muscle complex) in rats